AKTS Aktis Oncology, Inc.
USHealthcareAs of 2026-10-08
Why AKTS matters now
Aktis Oncology, Inc. (AKTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.74 with -1.44% on the session and $947.4M in market capitalization; recent performance reads 1-month +30.22% and YTD +7.54%.
The latest financial table shown here is Q1 2026, with revenue of $3.2M, net income of $-18.3M, and EPS of $-0.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.7%.
The latest indexable market news headline is "Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes ELI LILLY & Co filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
213.35
EV/EBITDA
-21.19
DCF Value
$2.14
FCF Yield
-4.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.2%
Operating Margin
-924.0%
Net Margin
-754.9%
ROE
-130.3%
ROA
-7.9%
ROIC
-10.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.2M | $-18.3M | $-0.33 |
| Q4 2025 | $1.9M | $-15.1M | $-0.28 |
| FY 2025 | $6.5M | $-63.7M | $-1.19 |
| Q4 2024 | $933.0K | $-12.1M | $-0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.33
Target (Median)
$35.00
Target Range
$31.00 - $40.00
Trading Activity
Insider Trades
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.10
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.